Results 181 to 190 of about 31,832 (242)

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Transfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone‐Junior, José Bordin, Langhi Dante, Carla Dinardo   +11 more
wiley   +1 more source

Drug-Induced Subacute Cutaneous Lupus Secondary to Sulfasalazine. [PDF]

Cureus
Choi K, Truong L, Kang Y.
europepmc   +1 more source

Intramuscular pathways of maladaptation in overtraining syndrome

The Journal of Physiology, EarlyView.
Abstract figure legend The transition from adaptive overreaching to maladaptive overtraining and mechanisms through which excessive training load can lead to performance decline. Four interconnected pathophysiological domains are highlighted: neural fatigue, involving both central and peripheral components such as altered sensory feedback and reflex ...
Emily Shorter, Oscar Horwath, Sabrina Tzivia Barsky, Ferdinand von Walden, Johanna T. Lanner   +4 more
wiley   +1 more source

Association of Childhood Acute Leukemia With Autoimmune Diseases

International Journal of Cancer, Volume 159, Issue 5, Page 1188-1195, 1 September 2026.
A possible link exists between various pediatric autoimmune diseases (AIDs) and increased risk of childhood leukemia. Although immune dysregulation is a key feature of these conditions, the connection between them remains unclear. In this study, using cancer registry data in Finland, the authors examined associations between AIDs and childhood acute ...
Ida Pellikka, Julia Ventelä, Anssi Auvinen, Olli Lohi, Atte Nikkilä   +4 more
wiley   +1 more source

Two-sample Mendelian randomization analysis unveils a potential genetic association between rheumatic diseases and the risk of idiopathic pulmonary fibrosis. [PDF]

Medicine (Baltimore)
Tan W, Ding J, Wang J, Wang S.
europepmc   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Biologic Rescue With Tocilizumab: A Case of Refractory Chronic Pericardial Effusion in Systemic Sclerosis. [PDF]

JACC Case Rep
Delgadillo R, Roufeh E, Lavelle B, Nguyen K, de la Rosa A.   +4 more
europepmc   +1 more source

IgG4‐Related Disease Overlapping With Anti‐Acetylcholine Receptor Antibody–Positive Myasthenia Gravis

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background IgG4‐related disease (IgG4‐RD) is a systemic, immune‐mediated, fibroinflammatory disorder with multiorgan involvement and variable clinical presentation, often creating diagnostic difficulty. Myasthenia gravis (MG) is an antibody‐mediated autoimmune disorder of the neuromuscular junction, most commonly associated with anti ...
Yumiko Yoshida, Ayami Okuzumi, Yuka Hosaka, Yuji Tomizawa, Taku Hatano   +4 more
wiley   +1 more source

Increased lymphoma risk in patients with systemic manifestations of Sjögren's disease: a population-based study. [PDF]

Front Med (Lausanne)
Blázquez-Sánchez T, Torres-Roselló A, Llorca J, Mairal-Monesma J, Olivas-Vergara O, Largo R, Naredo E, González-Gay MÁ.   +7 more
europepmc   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6584-6594, August 2026.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source